Zomedica Announces Historic Acquisition of Leading Veterinary Tech Firm and Secures FDA Approval for AI-Powered Device
Ann Arbor, MI – In a groundbreaking move, Zomedica Corp. (NYSE American: ZOM) has announced the acquisition of VetTech Innovations, the global leader in advanced veterinary robotics and diagnostics, in a $750 million deal. This historic acquisition positions Zomedica as the dominant force in the $50 billion global veterinary market.
FDA Approves Revolutionary VetBot 360
In tandem with the acquisition, Zomedica revealed it has secured FDA approval for its VetBot 360, the world’s first AI-powered robotic assistant designed to perform minimally invasive surgeries and complex diagnostics for pets. This cutting-edge device is expected to revolutionize veterinary practices by drastically reducing procedure times, improving outcomes, and cutting costs.
The VetBot 360 is equipped with machine learning capabilities that allow it to adapt to different surgical procedures and diagnostic needs, a game-changer for veterinarians and pet owners alike. Initial trials in partnership with Banfield Pet Hospitals showed that VetBot 360 reduced surgery times by 40% and improved recovery rates by 30%.
Strategic Partnerships with Global Chains
Zomedica also announced exclusive multi-year partnerships with Petco and Chewy, integrating VetBot services with their networks and opening a direct-to-consumer diagnostics service. This will allow pet owners to access at-home testing kits, analyzed using Zomedica’s proprietary AI algorithms.
Financial Growth Outlook
The company projects annual revenue to exceed $1 billion by 2027, a dramatic increase from its current revenue levels. CEO Larry Heaton stated, “This acquisition and the launch of VetBot 360 mark a new era for Zomedica. We’re not just innovating—we’re defining the future of veterinary medicine.”
